Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

April 30, 2014 updated by: Cumberland Pharmaceuticals

A Phase 1, Open-Label Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects with Normal Hepatic Function:

    • Weighs at least 45 kg
    • Body mass index between 18 and 40 kg/m2 inclusive
    • Must have normal hepatic function

  • Hepatic Impaired Subjects:

    • Weighs at least 45 kg
    • Meets criteria for mild or moderate hepatic impairment defined by Child-Pugh method
    • Body mass index between 18 and 40 kg/m2 inclusive

Exclusion Criteria:

  • Subjects with Normal Hepatic Function:

    • Smokes more than 10 cigarettes per day
    • Known to be HIV positive or has HIV antibodies
    • Has clinically significant history or presence of illness, malignancy, or immunodeficiency
    • Is Hepatitis A, B, or C positive
    • Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration
    • History of substance abuse within 6 months prior to screening

  • Hepatic Impaired Subjects:

    • Has history or presence of biliary obstruction or biliary disease, hepatic encephalopathy, advanced acidities, portal hypertension, or biliary liver cirrhosis
    • Is hypovolemic or has evidence of orthostatic hypotension
    • Smokes more than 10 cigarettes per day
    • Known to be HIV positive or has HIV antibodies
    • Has clinically significant history or presence of illness, malignancy, or immunodeficiency
    • Has clinically significant history or presence of GI symptoms other than those associated with moderate hepatic impairment
    • Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration
    • History of substance abuse within 6 months prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1. Mildly Hepatic Impaired Subjects
Drug: conivaptan hydrochloride
intravenous
Other Names:
  • YM087
  • Vaprisol
Experimental: 2. Moderately Hepatic Impaired Subjects
Drug: conivaptan hydrochloride
intravenous
Other Names:
  • YM087
  • Vaprisol
Experimental: 3. Subjects with Normal Hepatic Function
Drug: conivaptan hydrochloride
intravenous
Other Names:
  • YM087
  • Vaprisol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Measure PK and protein binding of conivaptan
Time Frame: 5 days
5 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Measure tolerability of conivaptan
Time Frame: 5 days
5 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cumberland Pharmaceuticals

Investigators

  • Study Director: Art Wheeler, MD, Cumberland Pharmaceuticals, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2009

Primary Completion (Actual)

January 1, 2010

Study Completion (Actual)

January 1, 2010

Study Registration Dates

First Submitted

February 23, 2009

First Submitted That Met QC Criteria

February 23, 2009

First Posted (Estimate)

February 25, 2009

Study Record Updates

Last Update Posted (Estimate)

May 2, 2014

Last Update Submitted That Met QC Criteria

April 30, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 087-CL-086

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Disease

Clinical Trials on conivaptan hydrochloride

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe